Dotatate

Star0

DB14554ApprovedInvestigationalSmall molecule

Dotatate: Overview.

Mechanism: Pharmacologically active on Somatostatin receptor type 2 and Somatostatin receptor
Curator reviewed
Formula / weight: C₆₅H₉₀N₁₄O₁₉S₂ · 1435.63 g/mol (avg)
First approval: United States, 2016
Also known as: DOTA-octreotate · DOTA-TATE · Oxodotreotide

Resolves to

Compound

UNIIMRL3739G66CAS177943-88-3ChEMBLCHEMBL441920

Clinical / RWD

RxNorm1797118

Structure

InChIKeyQVFLVLMYXXNJDT-CSBVGUNJSA-NSMILES

C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O

Targets

P30874SSTR2

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

42Clinical trialsPhase, status and sponsor resolved per trial

1Marketed productAcross 1 country and 1 labeller

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dotatate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account